Teva to Acquire NuPathe for $144 Million, Outbidding Endo

Teva Pharmaceutical Industries Ltd. agreed to buy NuPathe Inc. for $144 million, outbidding Endo Health Solutions Inc. to gain NuPathe’s migraine patch.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.